[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100629398":3},{"organization":4,"outcomesModule":7,"designInfo":36,"detailedDescription":39,"studyPopulation":40,"armGroups":41,"interventions":47,"overallOfficials":11,"centralContacts":53,"locations":59,"responsibleParty":78,"collaborators":11,"id":80,"slug":11,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":11,"eligibilityCriteria":85,"healthyVolunteers":81,"sex":86,"minAge":87,"maxAge":11,"enrollmentInfo":88,"targetDuration":11,"studyType":91,"phases":11,"briefSummary":92,"conditions":93,"keywords":11,"overallStatus":95,"whyStopped":11,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Steno Diabetes Center Copenhagen","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Time in range",null,"Last 2 weeks compared with 2 weeks before 780G start",[14,16,19,22,24,27,30,33],{"measure":15,"description":11,"timeFrame":12},"Time above and below range",{"measure":17,"description":11,"timeFrame":18},"HbA1c","Compared with HbA1c before 780G",{"measure":20,"description":11,"timeFrame":21},"Body weight","Compared with bodyweight before 780G start",{"measure":23,"description":11,"timeFrame":12},"Mean sensor glucose",{"measure":25,"description":11,"timeFrame":26},"Glycemic variability","last 2 weeks compared with 2 weeks before 780G start",{"measure":28,"description":11,"timeFrame":29},"Diabetes treatment satisfaction score","compared with DTQS before 780G start",{"measure":31,"description":11,"timeFrame":32},"Hypoglycaemia Fear Survey scores","Compared with before 780G start",{"measure":34,"description":11,"timeFrame":35},"Diabetes Distress Scale scores","compared with before 780G start",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":37,"timePerspective":38,"maskingInfo":11},"COHORT","CROSS_SECTIONAL","40 participants, who have completed the Steno780G trial, will be invited to attend a follow-up visit at Steno Diabetes Center Copenhagen between 3.5 - 4.5 years after start of AID treatment to assess the long-term effects of the MiniMed 780G system.","Study participants who have previously participated in the Steno780G study will be invited for a follow-up visit",[42],{"label":43,"type":11,"description":44,"interventionNames":45},"Cohort of 780G users","Cohort of 780G users who previously participated in the Steno780G trial",[46],"Device: 780G AID pump",[48],{"type":49,"name":50,"description":51,"armGroupLabels":52,"otherNames":11},"DEVICE","780G AID pump","Long term follow-up",[43],[54],{"name":55,"role":56,"phone":57,"phoneExt":11,"email":58},"Merete Christensen, MD, PhD","CONTACT","+45 29429113","merete.bechmann.christensen@regionh.dk",[60],{"facility":5,"status":11,"city":61,"state":11,"zip":62,"country":63,"countryCode":64,"cosmosGeoPoint":65,"geoPoint":70,"contacts":71},"Herlev","2730","Denmark","DK",{"type":66,"coordinates":67},"Point",[68,69],12.43998,55.72366,{"lat":69,"lon":68},[72,73,75],{"name":55,"role":56,"phone":57,"phoneExt":11,"email":58},{"name":55,"role":74,"phone":11,"phoneExt":11,"email":11},"PRINCIPAL_INVESTIGATOR",{"name":76,"role":77,"phone":11,"phoneExt":11,"email":11},"Kirsten Norgaard, Professor","SUB_INVESTIGATOR",{"type":79,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100629398",false,"NCT07474155","Steno780G Follow-up Study","Advanced Hybrid Closed-Loop Treatment in Adults With Type 1 Diabetes Not Meeting Glycaemic Targets - The Steno780G Follow-up Study","Inclusion Criteria:\n\n* Previous participation in the Steno780G study\n\nExclusion Criteria:\n\n* Lack of compliance with key study procedures at the discretion of the investigator.","ALL","18 Years",{"count":89,"type":90},40,"ESTIMATED","OBSERVATIONAL","Automated insulin delivery systems, also known as closed-loop systems, have shown to improve TIR, TAR, and TBR compared with insulin pump and CGM systems that cannot automatically dose insulin. Only few studies have described long-term use of AID systems over several years. Real-world studies suggest that the beneficial effects of AID systems on glycemic outcomes are sustained over time; however, a modest increase in body weight has been observed in some users, raising concerns about the metabolic trade-offs of improved glycemia. We aim to explore wether the improvements in glycemic outcomes and treatment satisfaction achieved with AID systems remain stable over multiple years, and secondly, if long-term treatment with AID systems may be associated with an increase in body weight.",[94],"Type 1 Diabetes","NOT_YET_RECRUITING","2026-03-10",{"date":98,"type":99},"2026-03-16","ACTUAL",{"date":101,"type":90},"2026-03",{"date":103,"type":90},"2026-10",{"name":5,"class":6},1]